Nasdaq · CIK 0002023658
BCAX Bicara Therapeutics Inc.
Insider trading from SEC Form 4. Last filing 32 d ago. Close $17.50 on Oct 9, 2026, +26% from the 52-week low and -42% from the high.
Last 90 days
Net insider value
-$401k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$401k by 1 insider
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
BCAXOct 9, 2026 · close 17.50
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Bicara Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 6Weak | Ryan Cohlhepp President, COO & Interim CEO sell | $401k 17,500 shares | -9% | - | |
| 6Weak | Ivan Hyep Chief Financial Officer sell | $168k 9,200 shares | -6% | +110% from low-4% from high | |
| 6Weak | Ryan Cohlhepp President and COO sell | $234k 12,500 shares | -6% | +111% from low-4% from high | |
| 13Weak | Ryan Cohlhepp President and COO sell | $226k 12,500 shares | -6% | +107% from low-15% from high | |
| 22Weak | Ivan Hyep Chief Financial Officer sell | $341k 18,400 shares | -13% | +107% from low-15% from high | |
| 32Weak | Claire Mazumdar Chief Executive Officer sell | $776k 41,163 shares | -12% | +117% from low-11% from high | |
| 17Weak | David Raben Chief Medical Officer sell | $205k 11,000 shares | -27% | +117% from low-11% from high | |
| 22Weak | Claire Mazumdar Chief Executive Officer sell | $454k 24,103 shares | -7% | +114% from low-26% from high | |
| 13Weak | Ryan Cohlhepp President and COO sell | $227k 12,500 shares | -6% | +116% from low-25% from high | |
| 22Weak | Claire Mazumdar Chief Executive Officer sell | $467k 24,734 shares | -8% | +113% from low-27% from high | |
| 12Weak | Ivan Hyep Chief Financial Officer sell | $117k 6,415 shares | -4% | +110% from low-28% from high | |
| 21Weak | David Raben Chief Medical Officer sell | $406k 22,000 shares | -38% | +110% from low-28% from high | |
| 29Weak | Ryan Cohlhepp President and COO sell | $912k 50,500 shares | -21% | +107% from low-28% from high | |
| 26Weak | Ivan Hyep Chief Financial Officer sell | $553k 30,385 shares | -20% | +107% from low-28% from high | |
| 33Weak | Lara Meisner Chief Legal Officer sell | $499k 33,807 shares | -100% | +59% from low-46% from high | |
| 12Weak | Lara Meisner Chief Legal Officer sell | $182k 15,829 shares | -100% | +31% from low-58% from high | |
| 11Weak | Lara Meisner Chief Legal Officer sell | $165k 15,829 shares | -100% | +8% from low-63% from high | |
| 25Weak | Lara Meisner Chief Legal Officer sell | $1.0M 79,146 shares | -100% | - |
Transactions
The last 99 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Ryan Cohlhepp President, COO & Interim CEO | MOption exercise Common Stock10b5-1 | +17,500 | $3.79 | $66k | 199,141 | 32 d ago |
| Sep 8, 2026 | Ryan Cohlhepp President, COO & Interim CEO | SOpen-market sale Common Stock10b5-1 | -14,058 | $22.77 | $320k | 185,083 | 32 d ago |
| Sep 8, 2026 | Ryan Cohlhepp President, COO & Interim CEO | SOpen-market sale Common Stock10b5-1 | -3,442 | $23.43 | $81k | 181,641 | 32 d ago |
| Sep 8, 2026 | Ryan Cohlhepp President, COO & Interim CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,500 | $0.00 | $0 | 34,252 | 32 d ago |
| Dec 26, 2025 | David Raben Chief Medical Officer | MOption exercise Common Stock | +19,789 | $3.79 | $75k | 55,286 | Dec 29, 2025 |
| Dec 26, 2025 | Ryan Cohlhepp President and COO | MOption exercise Common Stock | +25,000 | $4.44 | $111k | 214,141 | Dec 29, 2025 |
| Dec 26, 2025 | David Raben Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative | -19,789 | $0.00 | $0 | 98,987 | Dec 29, 2025 |
| Dec 26, 2025 | Ryan Cohlhepp President and COO | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 39,909 | Dec 29, 2025 |
| Dec 22, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Common Stock10b5-1 | +9,200 | $3.79 | $35k | 154,555 | Dec 23, 2025 |
| Dec 22, 2025 | Ivan Hyep Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -9,200 | $18.31 | $168k | 145,355 | Dec 23, 2025 |
| Dec 22, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,200 | $0.00 | $0 | 88,984 | Dec 23, 2025 |
| Dec 16, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Common Stock | +29,500 | $5.45 | $161k | 339,392 | Dec 18, 2025 |
| Dec 16, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -29,500 | $0.00 | $0 | 565,512 | Dec 18, 2025 |
| Dec 15, 2025 | Ryan Cohlhepp President and COO | MOption exercise Common Stock10b5-1 | +8,000 | $3.79 | $30k | 201,641 | Dec 16, 2025 |
| Dec 15, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -8,000 | $18.68 | $149k | 193,641 | Dec 16, 2025 |
| Dec 15, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -4,500 | $18.68 | $84k | 189,141 | Dec 16, 2025 |
| Dec 15, 2025 | Ryan Cohlhepp President and COO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 141,334 | Dec 16, 2025 |
| Nov 21, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Common Stock10b5-1 | +605 | $3.79 | $2,293 | 145,960 | Nov 25, 2025 |
| Nov 21, 2025 | Ryan Cohlhepp President and COO | MOption exercise Common Stock10b5-1 | +8,000 | $3.79 | $30k | 206,141 | Nov 25, 2025 |
| Nov 24, 2025 | David Raben Chief Medical Officer | MOption exercise Common Stock10b5-1 | +5,500 | $3.79 | $21k | 40,997 | Nov 25, 2025 |
| Nov 24, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Common Stock10b5-1 | +41,163 | $3.79 | $156k | 351,055 | Nov 25, 2025 |
| Nov 21, 2025 | Ivan Hyep Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -605 | $18.15 | $11k | 145,355 | Nov 25, 2025 |
| Nov 21, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -8,000 | $18.05 | $144k | 198,141 | Nov 25, 2025 |
| Nov 24, 2025 | David Raben Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,500 | $18.45 | $101k | 35,497 | Nov 25, 2025 |
| Nov 24, 2025 | Claire Mazumdar Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -41,163 | $18.86 | $776k | 309,892 | Nov 25, 2025 |
| Nov 24, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Common Stock10b5-1 | +17,795 | $3.79 | $67k | 163,150 | Nov 25, 2025 |
| Nov 21, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -4,500 | $18.05 | $81k | 193,641 | Nov 25, 2025 |
| Nov 24, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -41,163 | $0.00 | $0 | 236,107 | Nov 25, 2025 |
| Nov 25, 2025 | David Raben Chief Medical Officer | MOption exercise Common Stock10b5-1 | +4,594 | $3.79 | $17k | 40,091 | Nov 25, 2025 |
| Nov 24, 2025 | Ivan Hyep Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -17,795 | $18.55 | $330k | 145,355 | Nov 25, 2025 |
| Nov 25, 2025 | David Raben Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -4,594 | $18.84 | $87k | 35,497 | Nov 25, 2025 |
| Nov 21, 2025 | Ryan Cohlhepp President and COO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 149,334 | Nov 25, 2025 |
| Nov 25, 2025 | David Raben Chief Medical Officer | MOption exercise Common Stock10b5-1 | +906 | $3.79 | $3,434 | 36,403 | Nov 25, 2025 |
| Nov 21, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -605 | $0.00 | $0 | 115,979 | Nov 25, 2025 |
| Nov 25, 2025 | David Raben Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -906 | $18.84 | $17k | 35,497 | Nov 25, 2025 |
| Nov 24, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,795 | $0.00 | $0 | 98,184 | Nov 25, 2025 |
| Nov 24, 2025 | David Raben Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,500 | $0.00 | $0 | 123,370 | Nov 25, 2025 |
| Nov 25, 2025 | David Raben Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,594 | $0.00 | $0 | 118,776 | Nov 25, 2025 |
| Nov 25, 2025 | David Raben Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -906 | $0.00 | $0 | 69,413 | Nov 25, 2025 |
| Oct 16, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Common Stock10b5-1 | +24,103 | $3.79 | $91k | 333,995 | Oct 20, 2025 |
| Oct 16, 2025 | Claire Mazumdar Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -24,103 | $18.83 | $454k | 309,892 | Oct 20, 2025 |
| Oct 16, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -24,103 | $0.00 | $0 | 277,270 | Oct 20, 2025 |
| Oct 15, 2025 | Ryan Cohlhepp President and COO | MOption exercise Common Stock10b5-1 | +8,000 | $3.79 | $30k | 210,641 | Oct 16, 2025 |
| Oct 15, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -8,000 | $18.16 | $145k | 202,641 | Oct 16, 2025 |
| Oct 15, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -4,500 | $18.16 | $82k | 198,141 | Oct 16, 2025 |
| Oct 15, 2025 | Ryan Cohlhepp President and COO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 157,334 | Oct 16, 2025 |
| Oct 13, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Common Stock10b5-1 | +11,445 | $3.79 | $43k | 321,337 | Oct 15, 2025 |
| Oct 13, 2025 | Claire Mazumdar Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -11,445 | $18.92 | $217k | 309,892 | Oct 15, 2025 |
| Oct 15, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Common Stock10b5-1 | +13,289 | $3.79 | $50k | 323,181 | Oct 15, 2025 |
| Oct 15, 2025 | Claire Mazumdar Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -13,289 | $18.84 | $250k | 309,892 | Oct 15, 2025 |
| Oct 13, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,445 | $0.00 | $0 | 314,662 | Oct 15, 2025 |
| Oct 15, 2025 | Claire Mazumdar Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,289 | $0.00 | $0 | 301,373 | Oct 15, 2025 |
| Oct 9, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Common Stock10b5-1 | +6,415 | $3.79 | $24k | 151,770 | Oct 10, 2025 |
| Oct 9, 2025 | David Raben Chief Medical Officer | MOption exercise Common Stock10b5-1 | +22,000 | $3.79 | $83k | 57,497 | Oct 10, 2025 |
| Oct 9, 2025 | Ivan Hyep Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -6,415 | $18.23 | $117k | 145,355 | Oct 10, 2025 |
| Oct 9, 2025 | David Raben Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -22,000 | $18.45 | $406k | 35,497 | Oct 10, 2025 |
| Oct 9, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,415 | $0.00 | $0 | 116,584 | Oct 10, 2025 |
| Oct 9, 2025 | David Raben Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,000 | $0.00 | $0 | 128,870 | Oct 10, 2025 |
| Oct 6, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Common Stock10b5-1 | +6,514 | $3.79 | $25k | 151,869 | Oct 8, 2025 |
| Oct 6, 2025 | Ryan Cohlhepp President and COO | MOption exercise Common Stock10b5-1 | +24,000 | $3.79 | $91k | 245,141 | Oct 8, 2025 |
| Oct 6, 2025 | Ivan Hyep Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -6,514 | $18.17 | $118k | 145,355 | Oct 8, 2025 |
| Oct 6, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -24,000 | $18.06 | $433k | 221,141 | Oct 8, 2025 |
| Oct 7, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Common Stock10b5-1 | +18,244 | $3.79 | $69k | 163,599 | Oct 8, 2025 |
| Oct 6, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -15,600 | $18.06 | $282k | 205,541 | Oct 8, 2025 |
| Oct 7, 2025 | Ivan Hyep Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -18,244 | $18.22 | $332k | 145,355 | Oct 8, 2025 |
| Oct 7, 2025 | Ryan Cohlhepp President and COO | MOption exercise Common Stock10b5-1 | +8,000 | $3.79 | $30k | 213,541 | Oct 8, 2025 |
| Oct 7, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -8,000 | $18.06 | $144k | 205,541 | Oct 8, 2025 |
| Oct 8, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Common Stock10b5-1 | +5,627 | $3.79 | $21k | 150,982 | Oct 8, 2025 |
| Oct 7, 2025 | Ryan Cohlhepp President and COO | SOpen-market sale Common Stock10b5-1 | -2,900 | $18.06 | $52k | 202,641 | Oct 8, 2025 |
| Oct 8, 2025 | Ivan Hyep Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -5,627 | $18.21 | $102k | 145,355 | Oct 8, 2025 |
| Oct 6, 2025 | Ryan Cohlhepp President and COO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -24,000 | $0.00 | $0 | 173,334 | Oct 8, 2025 |
| Oct 6, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,514 | $0.00 | $0 | 146,870 | Oct 8, 2025 |
| Oct 7, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,244 | $0.00 | $0 | 128,626 | Oct 8, 2025 |
| Oct 7, 2025 | Ryan Cohlhepp President and COO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 165,334 | Oct 8, 2025 |
| Oct 8, 2025 | Ivan Hyep Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,627 | $0.00 | $0 | 122,999 | Oct 8, 2025 |
| Sep 29, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Common Stock10b5-1 | +33,807 | $9.24 | $312k | 33,807 | Oct 1, 2025 |
| Sep 29, 2025 | Lara Meisner Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -33,807 | $14.75 | $499k | 0 | Oct 1, 2025 |
| Sep 29, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -33,807 | $0.00 | $0 | 101,423 | Oct 1, 2025 |
| Sep 15, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Common Stock10b5-1 | +15,829 | $5.45 | $86k | 15,829 | Sep 17, 2025 |
| Sep 15, 2025 | Lara Meisner Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -15,829 | $11.49 | $182k | 0 | Sep 17, 2025 |
| Sep 15, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,085 | $0.00 | $0 | 54,769 | Sep 17, 2025 |
| Sep 15, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,744 | $0.00 | $0 | 87,699 | Sep 17, 2025 |
| Jun 16, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Common Stock10b5-1 | +15,829 | $5.45 | $86k | 15,829 | Jun 18, 2025 |
| Jun 16, 2025 | Lara Meisner Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -15,829 | $10.43 | $165k | 0 | Jun 18, 2025 |
| Jun 16, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,085 | $0.00 | $0 | 60,854 | Jun 18, 2025 |
| Jun 16, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,744 | $0.00 | $0 | 97,443 | Jun 18, 2025 |
| Jun 9, 2025 | Nils Lonberg director | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Jun 9, 2025 | Kate Haviland director | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Jun 9, 2025 | Kiran Mazumdar-Shaw director, owner | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Jun 9, 2025 | Michael Powell director | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Jun 9, 2025 | Scott M. Robertson director | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Jun 9, 2025 | Jake Simson director | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Jun 9, 2025 | Christopher Bowden director | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Jun 9, 2025 | Ra Capital Management, L.p. director, owner | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnotes | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Mar 14, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Common Stock10b5-1 | +79,146 | $5.45 | $431k | 79,145 | Mar 18, 2025 |
| Mar 14, 2025 | Lara Meisner Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -48,526 | $12.69 | $616k | 30,620 | Mar 18, 2025 |
| Mar 14, 2025 | Lara Meisner Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -30,620 | $13.24 | $406k | 0 | Mar 18, 2025 |
| Mar 14, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -48,720 | $0.00 | $0 | 107,187 | Mar 18, 2025 |
| Mar 14, 2025 | Lara Meisner Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,246 | $0.00 | $0 | 67,119 | Mar 18, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Christopher Bowdendirector
- Ryan CohlheppPresident and COO
- Kate Havilandceo, officer, director
- Ivan HyepChief Financial Officer
- Nils Lonbergdirector
- Claire MazumdarChief Executive Officer
- Kiran Mazumdar-Shawdirector, owner
- Lara MeisnerChief Legal Officer
- Michael Powelldirector
- Ra Capital Management, L.p.owner, director
- David RabenChief Medical Officer
- Scott M. Robertsondirector
- Jake Simsondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.